Free lookups: 1/3 Unlock Pro
Clinical reference Find a medicine
Ctrl K
1 of 3 free lookups remaining Upgrade
New search Medicine profile Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine

Clinical medicine profile

Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine

Vaccine / immunological product

POM
Evidence state Source not available Reviewed 14 Aug 2026
Route
IM / SC / ORAL / ID
Schedule
POM
ATC
Not assigned
PPB status
registered
Patient advice Check interactions
Verification required

This profile needs source confirmation

A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.

01 Risk first

Safety essentials

The information most likely to change a prescribing or dispensing decision.

Contraindications

  • Anaphylaxis to prior dose or component.
  • Live vaccines contraindicated in significant immunosuppression and usually pregnancy.
  • Defer for moderate–severe acute illness.

Precautions

  • Temperature of 400C within 48 hours, not due to another identifiable cause, collapse or shock-like state within 48 hours, persistent crying lasting 3 hours, occurring within 48 hours, convulsions with or without fever, occurring within 3 days.
02 Point of care

Dosing matrix

Population and organ-function guidance, shown together for faster comparison.

Adult

0.5mL, three vaccine doses administered at intervals of at least 4 weeks.

Paediatric

See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.

Renal

N/A generally.

  • CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Hepatic

N/A generally.

03 Clinical use

Use, effects & interactions

Indications

  • active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from 6 weeks onwards.
  • Clinical selection for Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
  • Class context: Vaccine / immunological product.
  • Confirm site-specific dose, duration and monitoring before prescribing.

Adverse effects

  • [Diphtheria] Local pain, low-grade fever, myalgia.
  • Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products). [Pertussis] Adverse reactions vary by agent.
  • Counsel on common predictable effects and serious warning symptoms (allergy, severe rash, jaundice, unusual bleeding, severe GI symptoms, neurological changes).
  • Report suspected ADRs via national pharmacovigilance channels. [Hepatitis B vaccine] Local pain, low-grade fever, myalgia.
  • Serious: anaphylaxis, vaccine-specific rare events (e.g. intussusception historically with some rotavirus products).
  • Fixed-dose/multi-ingredient product.
  • Clinical details partially inherited from component monographs: Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine.
  • Confirm combination SmPC for exact dosing.
04 Pharmacology

Mechanism & disposition

Combination product.

Combination product.Component mechanism (Diphtheria / Tetanus…Immunoglobulins provide passive temporary…
Read complete mechanism

Combination product. Component mechanism (Diphtheria / Tetanus / Pertussis / Hepatitis B vaccine): MOA-ID_37 Vaccines present antigen to the adaptive immune system to generate protective antibodies and memory cells without causing full disease (or using attenuated/inactivated/subunit/mRNA platforms). Immunoglobulins provide passive temporary immunity.

Onset

Immune response days–weeks

Duration

Months–lifelong (schedule-dependent)

Route

IM / SC / ORAL / ID

Elimination

are product-specific. Consider food effects, protein binding, hepatic CYP/UGT

Half-life

when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC. [Hepatitis B vaccine] Not classical PK; immunogenicity and cold-chain integrity determine effectiveness.

05 Special populations

Pregnancy, lactation & diet

Pregnancy

[Diphtheria] Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided. [Pertussis] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist. [Hepatitis B vaccine] Inactivated vaccines (e.g. influenza, Tdap) often recommended; live vaccines generally avoided.

Lactation

[Diphtheria] Most vaccines compatible; live vaccines usually fine for breastfeeding mother. [Pertussis] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data. [Hepatitis B vaccine] Most vaccines compatible; live vaccines usually fine for breastfeeding mother.

06 Kenya market

Brands & loaded prices

From
Median
Listings0
BrandManufacturerPackObserved price
No reviewed brand listings are linked yet.
07 Provenance

Sources & review state

Primary sourceLocal active-ingredient clinical extract; Component monographs (multi-source pipeline); Professional class pharmacology (Vaccine / immunological product)
Last reviewed14 Aug 2026
EvidenceSource not available

Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.